Sign in
CompletedPhase 2

Unacylated Ghrelin to Improve Functioning in PAD

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
25 people enrolled
Started
8 Jul 2020
Ended
23 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ghrelin
  • Placebo
Record updated
9 November 2026

Who can take part

Age
55 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • 55 years and older
  • Presence of peripheral artery disease defined as either:; An ankle-brachial index (ABI) of less than or equal to 0.90 at the baseline study visit; Vascular lab evidence of PAD or angiographic evidence of PAD with ischemic leg symptoms during the six-minute walk and/or treadmill exercise stress test

Who cannot take part

  • Unwilling or unable to self-administer study drug
  • Planned lower extremity revascularization or other major surgery during the next four months
  • Lower extremity revascularization, major orthopedic surgery, cardiovascular event, coronary revascularization, or other major surgery in the previous three months
  • Major medical illness including renal disease requiring dialysis, lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who only use oxygen at night may still qualify.]
  • Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
  • Currently taking study drug(s) or has taken study drug(s) in past six months
  • The potential participant does not have adequate refrigeration for storing study drug; Vulnerable populations (fetuses, pregnant women, children, prisoners, and institutionalized persons) and adults unable to consent will not be included in the study
  • Current ulcer on bottom of foot. The participant may become eligible after the ulcer heals
  • Failure to successfully complete the study run-in
  • Increase in angina in last month or angina at rest
  • Visual impairment that limits walking ability
  • Significant liver or kidney impairment defined as two or more hepatic function enzymes > 3.0 times the upper limit of normal and/or eGFR < 20. [NOTE: participants who meet this criterion may undergo a re-test of hepatic function tests to determine whether initially elevated hepatic enzymes represented a transient or spurious phenomenon.]
  • Above- or below-knee amputation
  • Critical limb ischemia
  • Wheelchair-bound or requiring a cane or walker to ambulate
  • Walking is limited by a symptom other than PAD
  • Mini-Mental Status Examination (MMSE) score < 23
  • Non-English speaking
  • Women who are pregnant or who are pre-menopausal will not be eligible
  • Potential participants who recently participated in or are currently participating in a supervised treadmill exercise and those planning to begin a supervised treadmill exercise regimen will become eligible four months after their participation in the supervised treadmill exercise program has ended
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United States
  • University of ChicagoChicago, United States

About the trial

What the trial wants to find out

GIFT is a pilot, randomized, double-blinded clinical trial that will examine the effects of unacylated ghrelin on walking ability in people with peripheral artery disease (PAD) compared to placebo. Preliminary evidence suggests that unacylated ghrelin may improve blood flow to the extremities and promote improved skeletal muscle growth and energy use.

Read full original descriptionShow less

A total of 30 participants with PAD will be randomized to one of two groups: unacylated ghrelin injections or placebo injections . Participants will self-administer the study drug or placebo subcutaneously once daily for four months. The primary outcome is change in six-minute walk distance between baseline and 4-month follow-up

The 2 groups in the trial

  • Unacylated ghrelinExisting treatment, for comparison

    Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).

    Treatment: Ghrelin

  • PlaceboPlacebo, for comparison

    Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Unacylated Ghrelin to Improve Functioning in PAD: The GIFT Trial Phase II
Publications
Record updated
9 November 2026